RLAY Relay Therapeutics Inc
Price (delayed)
$3.41
Market cap
$578.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$500.17M
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Highlights
The EPS has increased by 15% year-on-year and by 10% since the previous quarter
The debt has contracted by 9% YoY and by 2.6% from the previous quarter
The equity has declined by 7% since the previous quarter but it is up by 3.4% year-on-year
Relay Therapeutics's revenue has plunged by 61% YoY
RLAY's gross profit has dropped by 61% year-on-year
Key stats
What are the main financial stats of RLAY
Market
Valuations
Earnings
Shares outstanding
169.52M
Market cap
$578.07M
Enterprise value
$500.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
48.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.98
Revenue
$10.01M
Gross profit
$10.01M
Operating income
-$385.67M
Net income
-$337.71M
EBIT
-$337.71M
EBITDA
-$332.24M
Free cash flow
-$251.13M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$1.76
Book value per share
$4.65
Revenue per share
$0.07
TBVPS
$6.08
Total assets
$871.3M
Total liabilities
$93.5M
Debt
$48.5M
Equity
$777.79M
Working capital
$758.48M
Debt to equity
0.06
Current ratio
15.95
Quick ratio
15.44
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-3,320.1%
Gross margin
100%
Net margin
-3,374.7%
Operating margin
-3,854%
Return on assets
-39.6%
Return on equity
-44.4%
Return on invested capital
-47.3%
Return on capital employed
-41.2%
Return on sales
-3,374.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLAY stock price
How has the Relay Therapeutics stock price performed over time
Intraday
-6.83%
1 week
-2.01%
1 month
-13.89%
1 year
-62.69%
YTD
-17.23%
QTD
-17.23%
Financial performance
How have Relay Therapeutics's revenue and profit performed over time
Revenue
$10.01M
Gross profit
$10.01M
Operating income
-$385.67M
Net income
-$337.71M
Gross margin
100%
Net margin
-3,374.7%
Relay Therapeutics's operating margin has plunged by 159% YoY but it has increased by 2.4% from the previous quarter
The net margin has plunged by 152% YoY but it has grown by 2.2% from the previous quarter
Relay Therapeutics's revenue has plunged by 61% YoY
RLAY's gross profit has dropped by 61% year-on-year
Growth
What is Relay Therapeutics's growth rate over time
Valuation
What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
0.73
P/S
48.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.98
The EPS has increased by 15% year-on-year and by 10% since the previous quarter
The P/B is 75% lower than the 5-year quarterly average of 2.9 and 39% lower than the last 4 quarters average of 1.2
The equity has declined by 7% since the previous quarter but it is up by 3.4% year-on-year
The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 563.9 and 9% less than its last 4 quarters average of 53.3
Relay Therapeutics's revenue has plunged by 61% YoY
Efficiency
How efficient is Relay Therapeutics business performance
The return on sales has dropped by 152% year-on-year but it has increased by 2.2% since the previous quarter
The ROA is down by 8% YoY but it is up by 2.9% QoQ
The return on invested capital has declined by 8% year-on-year but it has increased by 2.9% since the previous quarter
The company's return on equity fell by 4.7% YoY but it rose by 2.8% QoQ
Dividends
What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLAY.
Financial health
How did Relay Therapeutics financials performed over time
RLAY's quick ratio is down by 38% year-on-year and by 14% since the previous quarter
RLAY's current ratio is down by 37% year-on-year and by 13% since the previous quarter
The debt is 94% less than the equity
Relay Therapeutics's debt to equity has decreased by 14% YoY
The debt has contracted by 9% YoY and by 2.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.